Multibagger Selection: Claude Opus 5.5's picks
Claude Opus 5.5 picked URGN, AXTI, ETON, INOD, BKSY with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | URGN | — | 60% | — | — |
| 2 | AXTI | — | 58% | — | — |
| 3 | ETON | — | 50% | — | — |
| 4 | INOD | — | 52% | — | — |
| 5 | BKSY | — | 42% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +3.76% | +2.88% | 1.22x | 0 |
The model's market view
Small and mid-cap growth faces a demanding but not hostile setup. On 2026-10-22 the 10-year Treasury yield is near 5.0% (down about 14 bp today), the Nasdaq is down about 2.2% on AI-capex financing worries, VIX is about 19 and the Russell 2000 is roughly flat. High real rates compress long-duration multiples, so the strongest multibagger setups here are companies whose earnings inflect fast enough that current multiples fall sharply on forward numbers, not stories that depend on multiple expansion alone. The screen began with about 250 US-listed stocks between $250M and $5B market cap with quarterly revenue growth above 40%, using Yahoo Finance data. It was narrowed by gross margin, dollar liquidity, consensus revenue and EPS trajectories, and a verifiable dated catalyst. The five picks are a commercial-stage oncology launch, an AI-optics substrate capacity ramp, a profitable rare-disease specialty pharma, an AI data-services company, and a satellite-imagery company. In every case 3x requires the operating plan to land AND the market to pay a growth multiple; 5x and 10x are exceptional to implausible. Financial figures come from Yahoo Finance quoteSummary data (TTM or latest reported, as labelled) and cited articles. They were not reconciled line by line against SEC filings, and that limitation is flagged where it matters.
Why each pick
URGN
UroGen is a commercial-stage uro-oncology company. Its second product, ZUSDURI (mitomycin intravesical solution), is the first FDA-approved therapy for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC), a population of about 59,000 recurrent patients a year in the US per the company. Quarterly revenue (Yahoo Finance) accelerated from about $27M (Sep-2025 quarter) to $38M, $51M and $72M (Jun-2026 quarter). Consensus revenue is about $322M for 2026 (+193%) and $532M for 2027 (+65%), with EPS swinging from about -$0.24 (2026E) to about +$2.59 (2027E). At $34.60 the stock trades near 13x 2027E EPS, cheap for a launch still compounding. The FDA has also accepted the NDA for next-generation UGN-103, PDUFA June 14, 2027, which would extend the franchise with IP into 2044. Price: 34.60 USD, live regular-session Nasdaq real-time quote via Yahoo Finance at 2026-10-22T15:45:50Z.
AXTI
AXT makes indium phosphide (InP) and other compound-semiconductor substrates used in optical transceivers for AI data centers. Quarterly revenue jumped from about $27M (Mar-2026 quarter) to about $48M (Jun-2026 quarter) (Yahoo Finance). Analysts more than doubled 2027 revenue estimates between June 30 and September 30, to about $461M from about $222M (TIKR via Yahoo Finance, 2026-10-09). Consensus is about $218M for 2026 (+147%) and $461M for 2027 (+111%), with 2027E EPS of about $2.25. Management guided InP capacity to exit 2026 at about $60M per quarter and said doubling again could lift revenue to about $130M per quarter. The stock has fallen from a 52-week high of $143.16 to about $53, so expectations have compressed sharply. Price: 53.29 USD, live regular-session quote via Yahoo Finance at 2026-10-22T15:47:05Z.
ETON
Eton Pharmaceuticals is a profitable rare-disease and specialty pharma company that builds revenue by acquiring and launching niche products. In the past month it launched IMPAVIDO (miltefosine) in the US, announced 2026-09-28. It also signed an exclusive US licensing and supply agreement for an Aquestive Therapeutics epilepsy drug, announced 2026-10-14; the specific drug and deal terms were behind a paywall and are not confirmed here. Consensus revenue is about $150M for 2026 (+87%) and $220M for 2027 (+47%), with EPS rising from about $1.40 to $2.55. At $49.69 the stock trades near 19.5x 2027E EPS with EPS growth above 80%, a PEG well below 1.5. Price: 49.6925 USD, live regular-session quote via Yahoo Finance at 2026-10-22T15:43:50Z.
INOD
Innodata provides data engineering, annotation and evaluation services for AI model developers. Quarterly revenue rose from about $63M (Sep-2025 quarter) to $72M, $90M and $92M (Jun-2026 quarter) (Yahoo Finance). The company is profitable and generates cash: TTM operating margin is about 17%, operating cash flow about $196M and FCF about $170M. That FCF is unusually high against $317M of TTM revenue, possibly reflecting customer prepayments, and is not reconciled to filings. Consensus revenue is about $360M for 2026 (+43%) and $460M for 2027 (+28%), with EPS of about $1.65 and $2.09. The stock has fallen from a 52-week high of $125.14 to about $59, compressing the multiple to about 28x 2027E EPS. Price: 59.45 USD, live regular-session quote via Yahoo Finance at 2026-10-22T15:46:03Z.
BKSY
BlackSky operates a real-time satellite imagery and analytics constellation serving government and defense customers, and is deploying its Gen-3 satellites. It is the smallest pick (about $689M market cap), with high operating leverage if Gen-3 contracts scale. TTM revenue is about $109M (+50%), gross margin about 70%, and consensus revenue is about $142M for 2026 (+33%) and $193M for 2027 (+37%). Losses are narrowing on consensus: EPS of about -$1.09 in 2026 and -$0.36 in 2027. At about 3.6x 2027E revenue it trades well below peer Planet Labs, at about 8.4x (computed from Yahoo Finance market cap and consensus). Recent wins include expanded Gen-3 assured contracts with international defense customers announced 2026-10-22, described as seven-figure, so individually small. Price: 16.84 USD, live regular-session quote via Yahoo Finance at 2026-10-22T15:46:59Z.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 3 Pro | BHVN, SG, SMR, JOBY, RDW |
| Grok 4.5 | NRIX, INOD, LQDA, CELC, APLD |
| Muse Spark 1.1 | KOD, CAPR, IVA, RCUS, TPC |
| DeepSeek | INOD, ONDS, SVRA, AQST, INBX |
| GPT-6 | AMPX, BKSY, RCAT, ENVX, OUST |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.